Additional file 3: of Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Figure S2. IHC staining for ITGBL1. (DOCX 2489 kb

Additional file 1: of Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Detailed materials and methods. (DOCX 40 kb

Additional file 2: of Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Figure S1. The study design. (DOCX 32 kb

Additional file 5: of Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Table S2. Univariate and multivariate analysis of RFS in stage II patients of validation cohort. (DOCX 23 kb

Additional file 4: of Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Table S1. The clinicopathological features of patients in this study. (DOCX 21 kb

Supplementary Figure 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Figure 3: The MRC significantly predicted recurrence-free interval regardless of the adjuvant chemotherapy treatment. The Kaplan Meier plots from: A, B, C and D) untreated patients; E, F, G and H) patients treated with 5-FU; A, B, E and F) from the fresh-frozen specimens in cohort-1; and C, D, G and H) from the FFPE specimens in cohorts 2 and 3.</p

Supplementary Table 3 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Table 3: Spearman's rho correlation coefficients of MRC vs clinicopathological risk factors for all the clinical cohorts.</p

Supplementary Figure 2 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Figure 2: CONSORT diagram for patients and specimens from both fresh-frozen and FFPE clinical validation cohorts. A) Fresh-frozen cohort (cohort-1), B) FFPE cohort (cohorts 2 and 3).</p

Supplementary Table 1 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Table 1: REMARK checklist.</p

Supplementary Figure 1 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Supplementary Figure 1: Recurrence prediction comparison between CMS and MRC in the A) TCGA discovery and B) Validation cohorts.</p